focus -WSS

focus

author：comprehensive 2025-10-02 22:23:47 - browse：673

Peter Marks. -- health coverage from STAT — Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. Susan Walsh-Pool/Getty Images

Peter Marks wants drug developers to ask more stupid questions.

It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business, even when they have promising data.

The problems are numerous: The diseases are often exceptionally rare, limiting the potential market. Manufacturing at commercial quality is complex and expensive. Proving a drug works can be difficult, because there may be too few patients to run a traditional randomized study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

WSS

Information blocking fines are now fair game in health care

Novo Nordisk obesity pill bests Wegovy in early trial

Novo Nordisk obesity pill bests Wegovy in early trial

Why the quest to eradicate polio has stumbled

Neurocrine congenital adrenal hyperplasia trial succeeds

Change Healthcare payments predicted restored March 15

leisure time

focus

hotspot

Virginia high school admissions case could be legal follow

Transgender sports debate: Physicians say bans are health issue

Continuity nursing helped my family in our darkest PICU moments

David Liu startup to focus on CRISPR delivery

Anesthesiologist group: stop taking Ozempic before surgery

Former medical device CEO who sold dummy, plastic parts convicted of fraud

After affirmative action ruling, medical educators look to 'holistic review'

FDA panel to weigh safety of artificial wombs for preterm births

Guidelines to prevent youth baseball injuries need more muscle

Patients, doctors press FTC to beef up hospital merger scrutiny

explore

How the messy conversation about Dolly changed bioethics

Eli Lilly CEO gives to Mike Pence presidential super PAC

CDC marks new Covid

What happened to the House vote on health price transparency?

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

What happened to the House vote on health price transparency?

knowledge

explore

hotspot

focus